Indication

Exanthema

1 clinical trial

1 product

Clinical trial

Topical Ruxolitinib as a Treatment of Anti-PD1 Induced Lichenoid Skin Toxicities: a Prospective Single-center Pilot Study

Status: Not yet recruiting, Estimated PCD: 2025-11-01

Product